Within the Core Unit for Molecular Tumor Diagnostics (CMTD) at the NCT Dresden, we aim to establish and validate the "next generation" of molecular diagnostic approaches in patients with brain tumors, in particular gliomas. Therefore, a comprehensive panel that includes more than 130 genes and for the first time regions involved in copy number changes in brain tumor was designed at the Department of Neuropathology in Heidelberg (Prof. Dr. med. Andreas von Deimling and Dr. med. Felix Sahm) together with Dr. med. Barbara Klink, Dresden.
This project aims to implement this panel at the NCT Dresden and apply it to FFPE glioblastoma tissue samples from a unique and clinically well-characterized study cohort consisting of non-responders and responders to treatment with radiotherapy in combination with temozolomide. We will establish a stratification algorithm to predict radio-resistance in glioblastoma and to identify patients suitable for innovative targeted therapies. The findings will directly translate into clinical practice. It is planned to implement the panel into routine diagnostic of brain tumors in Dresden to enable for a molecular-based treatment decision-making and initiation of future clinical trials.
- Development and clinical implementation of next generation sequencing based molecular diagnostics for patients with gliomas.
- Comprehensive characterization of brain tumors with one single experiment, an approach we will apply to other cancers as well in the future.
- Development of novel and innovative algorithms for the robust identification of CNVs from NGS-data, which can be used in many applications.